【申万宏源策略】周度研究成果（3.24-3.30）

Group 1 - The article emphasizes that the economic data validates the previously low expectations, indicating limited room for further downward adjustments [3] - The article discusses the potential for a strategic opportunity shift, with expectations for a comprehensive bull market by 2026 [7] - The article highlights the impact of U.S. tariffs on China, suggesting that the threat may dampen risk appetite, particularly with a sensitive window in Q2 2025 [8] Group 2 - The pharmaceutical sector has experienced four consecutive years of negative returns, but there is a significant probability of a sector rotation reversal in 2025 [9] - The article notes that while short-term sentiment indicators are high, overall market liquidity has not reached previous peaks, suggesting a cautious long-term outlook amidst rising technology industry trends [11] - The article outlines a cautious investment strategy for U.S. stocks, recommending hedging and timely profit-taking during potential rebounds, particularly in the tech sector [14]